A Phase II Trial of PALA + Dipyridamole in Patients with Advanced Soft-tissue Sarcoma

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1991 Jan 1

PMID 2040033

Citations 2

Authors

E S Casper

J Baselga

T B SMART

G B MAGILL

M Markman

A Ranhosky

Affiliations

Soon will be listed here.

Abstract

A total of 21 patients with advanced soft tissue sarcoma enrolled in a phase II trial of 3.5 g/m2 N-phosphonacetyl-L-aspartate (PALA) given intravenously every 3 weeks plus 50 mg/m2 dipyridamole (Persantine) given orally every 6 h. Dipyridamole administration was initiated 1 week before the first dose of PALA. Peak and trough plasma concentrations of dipyridamole were measured before and after the first dose of PALA in 14 patients. In all, 19 patients were evaluable for therapeutic response. One subject experienced partial regression of a pulmonary metastasis; no other major response was observed. Diarrhea was the most prominent toxicity; in one patient it was life-threatening and was associated with a severe rash. On the day preceding PALA administration, the median peak plasma concentration of dipyridamole was 2,208 ng/ml and the median trough value was 904 ng/ml. Similar values were obtained on the day of PALA administration. Although the levels achieved were similar to those required to modulate the activity of PALA in preclinical systems, the therapeutic results obtained in the present study were not superior to those reported for PALA alone in previously treated patients with soft-tissue sarcoma.

Citing Articles

Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism.

Liu Q, Gupta A, Okesli-Armlovich A, Qiao W, Fischer C, Smith M Cell Chem Biol. 2020; 27(6):668-677.e9.

PMID: 32442424 PMC: 7241336. DOI: 10.1016/j.chembiol.2020.05.002.

Dipyridamole combined with tumor necrosis factor-alpha enhances inhibition of proliferation in human tumor cell lines.

Suzuki N, Sekiya S, Sugano I, Kojima T, Yamamori H, Takakubo Y Jpn J Cancer Res. 1995; 86(8):761-9.

PMID: 7559100 PMC: 5920906. DOI: 10.1111/j.1349-7006.1995.tb02466.x.

References

Chan T, Markman M, Cleary S, Howell S . Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate. Cancer Res. 1986; 46(6):3168-72. View

Kurzrock R, Yap B, Plager C, Papdopoulos N, Benjamin R, Valdivieso M . Phase II evaluation of PALA in patients with refractory metastatic sarcomas. Am J Clin Oncol. 1984; 7(4):305-7. DOI: 10.1097/00000421-198408000-00002. View

Ervin T, Blum R, Meshad M, Kufe D, Johnson R, Canellos G . Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA). Cancer Treat Rep. 1980; 64(10-11):1067-71. View

Erlichman C, Strong J, Wiernik P, McAvoy L, Cohen M, Levine A . Phase I trial of N-(phosphonacetyl)-L-aspartate. Cancer Res. 1979; 39(10):3992-5. View

FISCHER P, WILLSON J, RisueNo C, Tutsch K, Bruggink J, Ranhosky A . Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion. Cancer Res. 1988; 48(19):5591-6. View

Grem J, FISCHER P . Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res. 1986; 46(12 Pt 1):6191-9. View

Bramwell V, Mouridsen H, Santoro A, Blackledge G, Somers R, Verwey J . Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987; 23(3):311-21. DOI: 10.1016/0277-5379(87)90075-7. View

Schoenfeld D, Rosenbaum C, Horton J, Wolter J, FALKSON G, DeConti R . A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 1982; 50(12):2757-62. DOI: 10.1002/1097-0142(19821215)50:12<2757::aid-cncr2820501211>3.0.co;2-j. View

Gralla R, Casper E, Natale R, Yagoda A, Young C . Phase I trial of PALA. Cancer Treat Rep. 1980; 64(12):1301-5. View

10.

Johnson R . Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo. Biochem Pharmacol. 1977; 26(1):81-4. DOI: 10.1016/0006-2952(77)90137-x. View

11.

Antman K, Crowley J, Balcerzak S, Rivkin S, Weiss G, Elias A . An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11(7):1276-85. DOI: 10.1200/JCO.1993.11.7.1276. View

12.

Borden E, Amato D, Rosenbaum C, ENTERLINE H, Shiraki M, Creech R . Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987; 5(6):840-50. DOI: 10.1200/JCO.1987.5.6.840. View

13.

Yap B, Baker L, Sinkovics J, Rivkin S, BOTTOMLEY R, Thigpen T . Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep. 1980; 64(1):93-8. View

14.

Darnowski J, Handschumacher R . Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools. Pharmacol Ther. 1989; 41(1-2):381-92. DOI: 10.1016/0163-7258(89)90115-0. View

15.

Baker L, Frank J, FINE G, Balcerzak S, Stephens R, Stuckey W . Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). J Clin Oncol. 1987; 5(6):851-61. DOI: 10.1200/JCO.1987.5.6.851. View

16.

Johnson R, Inouye T, Goldin A, Stark G . Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. Cancer Res. 1976; 36(8):2720-5. View

17.

Mahony C, Wolfram K, Cocchetto D, Bjornsson T . Dipyridamol kinetics. Clin Pharmacol Ther. 1982; 31(3):330-8. DOI: 10.1038/clpt.1982.42. View

18.

Plagemann P, Marz R, Wohlhueter R . Uridine transport in Novikoff rat hepatoma cells and other cell lines and its relationship to uridine phosphorylation and phosphorolysis. J Cell Physiol. 1978; 97(1):49-72. DOI: 10.1002/jcp.1040970107. View

19.

Antman K, Ryan L, Elias A, Sherman D, Grier H . Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989; 7(1):126-31. DOI: 10.1200/JCO.1989.7.1.126. View

20.

Wolfram K, Bjornsson T . High-performance liquid chromatographic analysis of dipyridamole in plasma and whole blood. J Chromatogr. 1980; 183(1):57-64. DOI: 10.1016/s0378-4347(00)81398-5. View